Drug name
Last update: Jul 2026Glecaprevir (G)
Developer(s)
Drug information
Glecaprevir
Maviret, Mavyret (when associated with Pibrentasvir)
Small molecule
DAA
Glecaprevir and Pibrentasvir (G/P) is a fixed-dose combination therapy indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 with or without compensated cirrhosis. G/P consists of two pangenotypic direct-acting antiviral agents: (1) Glecaprevir which targets the HCV non-structural viral protein 3/4A (NS3/4A) serine protease, and (2) Pibrentasvir which inhibits the HCV NS5A protein - both of which are essential for viral RNA replication and viron assembly. G/P is postulated to possess advantageous pharmacological properties - including suitable target plasma exposures, half-life duration and aqueous solubility - that could potentially enable the development of a cost-effective long-acting injectable formulation via particle-processing technologies.
Glecaprevir and Pibrentasvir (G/P) oral fixed-dose combination is FDA approved
Glecaprevir and Pibrentasvir (G/P) oral fixed-dose combination is FDA approved
Therapeutic area(s)
- HCV
- Treatment
Administration route
Oral, Intramuscular
Associated long-acting platforms
Aqueous drug particle suspension
Use of drug
- Administered by a nurse
- Administered by a specialty health worker
- Daily
Dosage
Not provided
Not provided
Not provided
Not provided
Not provided
Associated compounds, formulations and regimens
Glecaprevir Pibrentasvir LA injection
Associated technologies
CompareAdditional information
Developer(s)
AbbVie
AbbVie Inc. is a global biopharmaceutical company that manufactures and develops innovative medicines as part of a diversified portfolio across several therapeutic categories including immunology, oncology, neuroscience, aesthetics and eyecare. Headquartered in North Chicago, Illinois, AbbVie was founded in 2013 following a successful corporate spin-off from its parent company Abbott Laboratories.
Drug structure
Scale-up and manufacturing prospects
Long-acting formulations of Glecaprevir and Pibrentasvir (G/P) are still in the early stages of drug development and therefore manufacturing information is limited with few reported examples. One novel approach currently being pioneered by researchers at Tandem Nano Ltd. utilises a proprietary Solid Drug Nanoparticle (SDN) technology platform to achieve high levels of G/P drug loading (>500mg/mL). Interestingly, pre-clinical pharmacokinetic assessments displayed an apparent difference in the release kinetics of both drugs which could be related to differences in aqueous solubility.
Not provided
Proposed minimally acceptable characteristics for prospective long-acting G/P formulations include: (1) 12-month shelf life as a powder with no cold chain required, (2) suitable drug volume enabling a one monthly intramuscular injection, (3) manageable injection site reaction, and (4) cost equal or less than the oral therapy equivalent.
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided